Jumping on anti-aging bandwagon, Y Combinator joins hunt for the $100B pill
Anti-aging upstarts have been popping up across the biotech landscape, with a slate of biotechs racing towards a market opportunity worth untold billions to the winners — or so the treasure seekers tell us. And now, after making a name accelerating tech stars like Dropbox, Airbnb, and Stripe to the big-time, prominent early-stage Silicon Valley investor Y Combinator wants a piece of the anti-aging pot of gold.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.